Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displayed in OMB control Information.

		Application Number			10/58	10/580,615		
POWER OF ATTORNEY			International Application No.			PCT/IB04/03749		
			Filing Date			November 15, 2004		
			First Named Inventor			John W. Benbow		
and CORRESPONDENCE ADDRESS			Title			AmInopyrazole Derivatives As GSK-3 Inhibitors		
INDICATION FORM			Art Unit			Unknown		
			Examiner Name			Unknown		
			Attorney Docket Number			PC26048A		
I hereby appoint: Practitioners at Custo	2852	28523						
OR	<u> </u>			_				
Practitioners named below:								
	Registration Number							
Name				regional	on wan			
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.								
Please recognize or change the correspondence address for the above-identified application to:								
The above-mentioned Customer Number.								
OR								
The address associated with Customer Number								
OR								
Firm or Individual Name								
Address								
City		s	ate		Zîp			
Country			•					
Telephone		Fa	Κ.					
I am the:	· · · · · · · · · · · · · · · · · · ·							
Applicant/inventor.								
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).								
SIGNATURE of Applicant or Assignee of Record								
Name Daniel W. Kung								
Signature Danie Wicz								
Date 15 May 2607								
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.								
□ *Total of forms are submitted.								

This colocition of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the LIGPTO is process) an application. Confidentially is governed by 38 U.S.C. 122 and 37 CFR 1.41. This collection is estimated to take 3 minutes to the control of the co

PC26084A

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Application Number 10/580.615 International Application No. PCT/IB04/03749 Filing Date November 15, 2004 POWER OF ATTORNEY First Named Inventor John W. Benbow and Title Aminopyrazole Derivatives As GSK-3 CORRESPONDENCE ADDRESS Inhibitors INDICATION FORM Art Unit Unknown **Examiner Name** Unknown Attorney Docket Number PC26048A I hereby appoint: 28523 Practitioners at Customer Number OR Practitioners named below: Name Registration Number as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith. Please recognize or change the correspondence address for the above-identified application to: The above-mentioned Customer Number. OR The address associated with Customer Number OR Firm or Individual Name Address City State Zip Country Fax Telephone I am the: Applicant/Inventor. X Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). SIGNATURE of Applicant or Assignee of Record Name John W. Benbow en m Signature 007 NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple

This collection of information is required by 37 CER 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to fise (and by the USPTO to process) an application. Confidentially is opened by 58 U.S. C. 122 and 37 CER 1.41 fix located in its extended to base. Amount of the completed application form to the USPTO. The will vary depending upon the individual case. Any comments on the amount of time you require to complete in the form and/or supposers for frenducing bis burden; should be set to the Chief information Officer, U.S. Patient and Trademark Office, U.S. Department of Commence, P.O. Box 1460, Alexandriu, V.2.2313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.D. 6x 1446, Alexandriu, V.2.2313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.D. 6x 1446, Alexandriu, V.2.2313-1450.

forms if more than one signature is required, see below

forms are submitted.

□ *Total of